/TRVI
TRVI Stock - Trevi Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$13.01+6.73%
+$0.82 (+6.73%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+48.0%upside
Target: $19.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TRVI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.88 – $13.14
TARGET (TP)$19.25
STOP LOSS$11.97
RISK/REWARD1:6.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.83
52W High$14.39
52W Low$3.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-47,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-51,524,000 | $-33,923,000 | $-29,907,000 | $-32,476,000 | $-32,489,000 |
| Net Income | $-47,911,000 | $-29,065,000 | $-29,152,000 | $-33,940,000 | $-32,758,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.47 | $-0.29 | $-0.45 | $-1.49 | $-1.81 |
Company Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Visit WebsiteRating Distribution
Strong Buy
1
9%
Buy / Outperform
10
91%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish0 Neutral/Bearish
Price Targets
$14
Average Target
↑ 6.1% Upside
Now
$6
Low
$14
Average
$29
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Leerink Partners | Initiation | Outperform | $13 |
| August 21st 2025 | Morgan Stanley | Initiation | Overweight | $18 |
| July 1st 2025 | Cantor Fitzgerald | Initiation | Overweight | $25 |
| May 28th 2025 | H.C. Wainwright | Initiation | Buy | $21 |
| March 10th 2025 | Needham | Reiterated | Buy | $25← $8 |
| March 10th 2025 | Raymond James | Upgrade | Strong Buy | $29← $9 |
| December 12th 2024 | H.C. Wainwright | Reiterated | Buy | $7.5← $6 |
| September 9th 2024 | Leerink Partners | Resumed | Outperform | $7← $6 |
| August 30th 2024 | H.C. Wainwright | Initiation | Buy | $6 |
| August 30th 2024 | Raymond James | Initiation | Outperform | $9 |
| June 13th 2024 | Rodman & Renshaw | Initiation | Buy | $7 |
| April 12th 2023 | B. Riley Securities | Initiation | Buy | $6 |
| November 22nd 2022 | SVB Leerink | Initiation | Outperform | $6 |
Earnings History & Surprises
TRVIBeat Rate
72%
Last 18 quarters
Avg Surprise
+13.2%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.08vs$-0.10
Q2 24
-22.2%
$-0.11vs$-0.09
Q3 24
-9.1%
$-0.12vs$-0.11
Q4 24
-8.3%
$-0.13vs$-0.12
Q1 25
+8.3%
$-0.11vs$-0.12
Q2 25
+30.8%
$-0.09vs$-0.13
Q3 25
+10.0%
$-0.09vs$-0.10
Q4 25
+20.0%
$-0.08vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.13 | $-0.09 | +30.8% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.21 | $-0.14 | +33.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.31 | $-0.24 | +22.6% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.46 | $-0.49 | -6.5% | ✗ MISS |
Latest News
Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18
📈 PositiveBenzinga•Dec 19, 2025, 02:54 PM•Also:
Trevi Therapeutics Appoints Veteran Finance Leader David Hastings as New CFO Starting January 2026
📈 PositiveBenzinga•Dec 4, 2025, 12:33 PM
Trevi Therapeutics edges higher amid takeover speculation
📈 PositiveSeeking Alpha•Dec 2, 2025, 09:35 PM
Leerink Partners Maintains Outperform on Trevi Therapeutics, Raises Price Target to $16
📈 PositiveBenzinga•Nov 20, 2025, 06:53 PM
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $24
📈 PositiveBenzinga•Nov 14, 2025, 05:34 PM
Morgan Stanley Maintains Overweight on Trevi Therapeutics, Raises Price Target to $19
📈 PositiveBenzinga•Nov 14, 2025, 04:57 PM
Clear Street Maintains Buy on Trevi Therapeutics, Raises Price Target to $21
📈 PositiveBenzinga•Nov 14, 2025, 11:01 AM
Trevi Therapeutics Inc Files For Mixed Shelf; Size Not Disclosed; Says In Addition, Offering Of Up To $200M Of Common Stock
📉 NegativeBenzinga•Nov 13, 2025, 10:17 PM
Trevi Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:12 PM
Trevi Therapeutics Announced Two Accepted Abstracts For Presentation At The Chest 2025 Annual Meeting In Chicago, Oct 19–22, 2025
➖ NeutralBenzinga•Oct 8, 2025, 11:41 AM
Trevi Therapeutics Option Alert: Sep 19 $7 Calls Sweep (60) Near The Ask: 951 @ $1.249 vs 11 OI; Ref=$8.09
📈 PositiveBenzinga•Aug 27, 2025, 03:49 PM
Morgan Stanley Initiates Coverage On Trevi Therapeutics with Overweight Rating, Announces Price Target of $18
📈 PositiveBenzinga•Aug 21, 2025, 11:16 AM
Lisa Delfini To Resign As CFO Of Trevi Therapeutics On Aug 22; Jennifer L. Good To Serve As Interim Principal Financial Officer
➖ NeutralBenzinga•Aug 20, 2025, 08:35 PM•Also:
Frequently Asked Questions about TRVI
What is TRVI's current stock price?
Trevi Therapeutics, Inc. (TRVI) is currently trading at $13.01 per share. The stock has moved +6.73% today.
What is the analyst price target for TRVI?
The average analyst price target for TRVI is $19.25, based on 1 analyst.
What sector is Trevi Therapeutics, Inc. in?
Trevi Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TRVI's market cap?
Trevi Therapeutics, Inc. has a market capitalization of $1.67 billion, making it a small-cap company.
Does TRVI pay dividends?
No, Trevi Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
NVAX
Novavax, Inc.
$6.66
Mkt Cap: $1.1B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to TRVI for comparison